Lyophilised NAD+ keeps best sealed, desiccated, dark and frozen. Its dominant chemical vulnerability is alkaline conditions rather than temperature: the nicotinamide-ribose bond cleaves quickly above pH 7. Once dissolved, hold the stock slightly acidic, aliquot for single use, and date every container at the moment it is prepared.
- NAD+ degrades fastest by base-catalysed cleavage of the nicotinamide-ribose bond, so pH controls its fate more than freezer temperature does.
- NAD+ and NADH have opposite stability profiles: the oxidised form tolerates acid and fails in base, the reduced form does the reverse.
- Free-acid NAD+ is hygroscopic, so water content and assay from the certificate are needed to convert a nominal vial mass into a real concentration.
- A UV reading at 260 nm against an extinction coefficient near 18.0 mM-1 cm-1 gives an independent check on a prepared stock.
- Sodium phosphate buffers shift acidic on freezing, which happens to be the protective direction for NAD+ and the damaging one for NADH.
- Purity by chromatographic area and content by mass are separate numbers, and a competent certificate reports both.
NAD+ is a dinucleotide, and peptide handling rules do not transfer
β-Nicotinamide adenine dinucleotide, oxidised form, is a small molecule by the standards of this catalogue: an adenine nucleotide joined through a pyrophosphate bridge to a nicotinamide riboside. CAS 53-84-9, formula C21H27N7O14P2, formula weight 663.43 for the free acid. Material is supplied either as the free acid, usually as a hydrate, or as a mono- or disodium salt. Which one you have changes the formula weight, changes the pH of the solution you get when you dissolve it, and therefore changes both your concentration arithmetic and your stability window. The certificate should say. If it does not, that is the first question for the supplier.
Peptide storage guidance circulates widely enough that it gets applied to anything sold as a lyophilised white powder in a vial. Most of it is beside the point here. NAD+ has no peptide backbone to hydrolyse, no methionine to oxidise, and it does not aggregate at an air-water interface the way a lipidated peptide does, so agitation is a minor concern. What it has instead is a glycosidic bond to the nicotinamide ring that base attacks readily, a pyrophosphate linkage that acid and heat attack slowly, and a redox partner in NADH whose stability profile runs in the opposite direction. Handling NAD+ well means controlling water, then pH, then temperature, in about that order of consequence.
One practical consequence of the free-acid form: it is hygroscopic, and the water it picks up counts in the vial mass. A certificate that reports water content by Karl Fischer or loss on drying, alongside a purity assay, lets you correct nominal mass to actual NAD+ content. Without those two numbers, a stated 10 mg is a fill target rather than a quantity of compound, and every downstream concentration inherits the difference.
- Alkaline pH — cleaves the nicotinamide-ribose bond, the fastest route
- Water — moves the solid into the same regime as a solution
- Temperature — a rate modifier on every route
- Reducing agents in the diluent — quiet conversion to NADH
- Microbial glycohydrolases — enzymatic cleavage in a contaminated stock
The pH asymmetry that governs everything
The oxidised and reduced pyridine nucleotides are mirror images in their chemical vulnerability. NAD+ tolerates acid and degrades quickly in base. NADH tolerates base and degrades quickly in acid. Lowry, Passonneau and Rock quantified this in the early 1960s, and the finding has held up because it follows directly from the chemistry: hydroxide adds at the C4 position of the oxidised nicotinamide ring, and the resulting adducts go on to fluorescent products, while the reduced ring is the one that is acid-labile.
The lab consequence is that a routine assay buffer at pH 7.4 is not a neutral place to park an NAD+ stock, and anything above pH 8 is actively hostile. Prepare concentrated stock in unbuffered water or in a mildly acidic buffer, then dilute into the working buffer at the point of use rather than storing at working pH.
| Route | Products | What drives it | Practical control |
|---|---|---|---|
| Glycosidic cleavage at the nicotinamide-ribose bond | Nicotinamide plus ADP-ribose | Alkaline pH, heat, water activity | Keep solutions at or below neutral; keep powder dry |
| Base adduct formation at ring C4 | Fluorescent nicotinamide adducts | Hydroxide concentration | Never store or thaw in alkaline buffer |
| Pyrophosphate hydrolysis | NMN plus AMP | Strong acid, heat, prolonged storage in solution | Cold storage; avoid heating to dissolve |
| Reduction to NADH | NADH, then acid-labile in turn | Reducing agents in the diluent, such as thiols or dithionite | Check diluent composition before dissolving |
| Enzymatic cleavage | Nicotinamide, ADP-ribose, free phosphate | Microbial NAD glycohydrolases and phosphatases | Clean technique; filtered diluent; cold storage |
| Moisture uptake by the cake | No new species, but mass and rate errors | Ambient humidity, cold vial surfaces | Equilibrate before opening; reseal over desiccant |
Temperature is absent from the top of that list for the same reason it was absent in the peptide case. Cold slows all of these routes and is worth having. It does not address the pH of the solution the compound is sitting in.
Sealed powder: conditions by physical state
Dry, sealed and cold is a genuinely slow regime for this compound. Suppliers commonly specify minus 20 °C, desiccated, protected from light, and that specification is reasonable rather than decorative. Ambient shipping of the dry solid over a few days is a normal excursion and not the thing to worry about.
| State | Temperature | Light | Relative horizon | Why |
|---|---|---|---|---|
| Sealed powder, unopened | Minus 20 °C or below, over desiccant | Dark | Longest | Water excluded, all routes slowed |
| Sealed powder, in use | 2 to 8 °C, over desiccant | Dark | Shorter | Acceptable where the vial is consumed within a defined window |
| Powder in transit | Ambient | Dark, insulated | Days | The dry solid tolerates short excursions |
| Aqueous stock, near neutral or slightly acidic | 2 to 8 °C | Dark | Days | Hydrolysis is now running and microbial risk begins |
| Aqueous stock, single-use aliquots | Minus 20 °C or below | Dark | Weeks to months | Slow, provided each aliquot is thawed once |
| Working dilution at pH 7.4 or above | Use fresh | Dark | Hours | Alkaline cleavage is the fast route |
Those horizons are relative on purpose. A shelf life expressed in months belongs to a lot that has had a stability study run on it, in that container, under those conditions, on the design principles ICH Q1A(R2) sets out. Where no such study exists, the honest statement is that the window is unestablished, and the lot certificate is the only document with any standing to carry a date. Our own position on what a certificate should contain is set out in the quality standard.
Condensation and the hygroscopic cake
Take a vial out of a minus 20 freezer into a room at 22 °C and 60 percent relative humidity, and the glass sits far below the dew point. Break the seal at that moment and water condenses inside the vial, onto a lyophilised solid that is happy to take it up. Nothing about the appearance changes in any way a person can read. The vial then goes back to the freezer with water in it, and the next operator inherits a slightly different material than the label describes.
The control is dull and works: let the sealed vial reach room temperature before breaking the seal, every time. Twenty to thirty minutes on the bench suits a small vial. Work quickly once it is open, reseal over fresh desiccant, and log the excursion if the protocol tracks them.
There is a second reason to care about moisture here beyond degradation rate. A cake that has taken up water weighs more than the NAD+ it contains, so any gravimetric step done on partially hydrated material biases the concentration low. If a vial is being subdivided by weight rather than dissolved whole, that bias goes straight into the numbers and nothing downstream will reveal it.
Once it is in solution
Adding diluent starts a faster clock and introduces two variables that the dry solid did not have: the pH of the resulting solution and whatever microbial load came with the water and the technique. Free-acid NAD+ dissolved in water gives an acidic solution, which happens to sit in the protective direction for this compound. A sodium salt gives something closer to neutral. Either is preferable to dissolving directly into a Tris or bicarbonate buffer at pH 8.
Check what is in the diluent before you use it. Bacteriostatic water contains benzyl alcohol as a preservative and is roughly neutral; the general properties of that diluent are covered in the note on bacteriostatic water. Any diluent containing a thiol reducing agent will convert some fraction of the oxidised compound to NADH, which is a different analyte with the opposite acid-base sensitivity.
Freezing deserves one specific caution. Sodium phosphate buffers shift acidic on freezing as the dibasic salt crystallises out first, and the pH excursion can run one to two units. For NAD+ that shift is in the tolerable direction, so phosphate-buffered stocks survive freezing better than intuition suggests. The same excursion would be damaging for a reduced-nucleotide stock. Knowing which of the two you are freezing is the point.
Worked arithmetic. A nominal 10 mg vial brought into 2 mL of diluent gives:
10 mg ÷ 2 mL = 5 mg/mL
Converting to molar terms against a formula weight of 663.43 g/mol:
5 mg/mL ÷ 663.43 mg/mmol = 7.54 mmol/L
That figure assumes the vial contains 10 mg of anhydrous NAD+ at 100 percent purity, which it does not. Correct it with the assay and water content from the certificate before it goes into a method. The vial concentration calculator handles the arithmetic for other vial sizes and volumes.
A UV reading is a cheap independent check on that number. NAD+ absorbs at 260 nm with a molar extinction coefficient near 18.0 mM-1 cm-1 at neutral pH. A 200-fold dilution of the stock above gives about 37.7 µM, which should read near 0.68 AU in a 1 cm cell. If the measured value is well below prediction, the discrepancy is either in the fill mass, the water content, or the material.
Aliquot at the point of preparation. Split the stock into single-use volumes so that no container is thawed twice, and date each one in ink that survives a freezer. Repeated warming of a shared tube adds hydrolysis time at every cycle and gives microbial contamination an opportunity it would not otherwise get.
How degradation shows up analytically
NAD+ is straightforward to assay. Reversed-phase HPLC on a C18 column with an aqueous phosphate or ammonium acetate mobile phase, ion-pairing if retention is poor, detection at 260 nm, resolves the parent from its main degradants comfortably. System suitability expectations for that kind of method are the ordinary ones set out in USP General Chapter <621>. Where identity confirmation is required, LC-MS in negative mode gives the deprotonated parent near m/z 662, and the diagnostic fragment is loss of the nicotinamide ring at 122 Da.
| Observation | Likely cause | Where it shows |
|---|---|---|
| Early-eluting peak with strong 260 nm response | ADP-ribose from glycosidic cleavage | RP-HPLC purity trace |
| Small polar peak, weak 260 nm response | Free nicotinamide | RP-HPLC; positive-mode LC-MS near m/z 123 |
| Absorbance at 340 nm above baseline | NADH present, whether from reduction or from the original material | UV scan of the stock |
| Fluorescence on alkaline treatment | Base adducts of the nicotinamide ring | Fluorimetric check, historically the classic assay |
| Yellowing of the solid or solution | Advanced or heat-driven decomposition | Visual inspection |
| Total purity intact, assay low | Water content or fill mass, not degradation | Certificate cross-check |
The last row is the one people miss. A purity figure of 99 percent by area says nothing about how much material is in the vial. Purity and content are separate numbers and a competent certificate reports both.
What the record should say
Storage discipline that is not written down is not reproducible. For a prepared solution the minimum record is the source lot identifier, the diluent and its lot, the volume added, the resulting nominal and corrected concentration, the pH if it was measured, the date and time of preparation, and the initials of whoever made it. Aliquots inherit that record through a shared identifier written on the tube.
The reason is diagnostic rather than administrative. When a result comes back low, the first question is whether the material was what the method assumed. A record that runs from the sample back through the aliquot to the stock to the lot to the certificate answers that in a minute. A record that stops at the tube means repeating the work, and an undated tube is waste regardless of how recently someone believes it was made.
One habit worth adopting: record the diluent pH rather than assuming it. Free acid and sodium salt forms of the same nominal compound give solutions a couple of pH units apart, and for a compound whose main failure route is base-catalysed, that difference is the whole stability story.
Regulatory position
NAD+ is an endogenous coenzyme and a widely sold laboratory reagent. There is no FDA-approved injectable NAD+ drug product in the United States, and material supplied for laboratory work is not manufactured under the sterility, endotoxin and lot-release controls that a licensed parenteral would require. NAD+ has been among the bulk drug substances nominated for use in pharmacy compounding under section 503A; the current category assignment and the agency reasoning behind it should be read from FDA's published list rather than from secondary summaries, which lag.
Related precursors have their own status. In 2022 FDA responded to new dietary ingredient notifications for nicotinamide mononucleotide by concluding that NMN is excluded from the dietary supplement definition, on the basis that it had been authorised for investigation as a new drug. Nicotinamide riboside, by contrast, has cleared the notification route. These are distinct compounds with distinct regulatory histories and none of it changes what research-grade material is.
Status verified 26 August 2026.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Compound identifiers, salt form and current certificate for the material we stock are on the NAD+ product record.
What is NAD+ studied for?
Published research on NAD+ investigates the areas below, which is a different question from what NAD+ will do for anyone, a claim about a living system that nothing on this site is sold for.
What it is. Nicotinamide adenine dinucleotide, a helper molecule rather than a peptide.
What the research looks at. A very large basic-science record on how cells make energy, on oxidation and reduction, and on enzymes. Most of it is about what the molecule does inside cells rather than about any product sold in a vial.
How it is thought to work. It carries hydrogen back and forth in the reactions that make energy, switching between two forms, and it is also used up as raw material by two families of enzymes, the sirtuins and the PARPs. Its basic biochemistry is textbook material and nobody disputes it.
What is not established. Well-understood biochemistry says nothing about any particular preparation in a vial. NAD+ is chemically different from the precursors it is often lumped in with, and material of this kind pulls in water from the air and degrades in light, which makes the handling paperwork matter more than usual.
The full record, including the certificate for the lot in stock, is on the NAD+ product page.
Common questions
Does lyophilised NAD+ need to be frozen?
Why is pH more important than temperature for NAD+?
How long is a prepared aqueous stock usable?
Can I dissolve NAD+ directly in my assay buffer?
What does the certificate need to show for NAD+?
Is a yellow tint in the solution a problem?
More handling guides
Sources
- Lowry, Passonneau and Rock, Journal of Biological Chemistry, 1961. Measured the stability of the oxidised and reduced pyridine nucleotides in acid and base; establishes the opposing acid-base lability that governs NAD+ solution handling.
- PubChem compound record for NAD+, NIH National Library of Medicine. Source for molecular formula, formula weight, CAS number and salt-form identifiers cited in this article.
- ICH Q1A(R2), Stability Testing of New Drug Substances and Products. Framework for why a stated shelf life requires a study on that material in that container; supports treating unstudied storage windows as unestablished.
- USP General Chapter <621>, Chromatography. System suitability and method performance expectations for the reversed-phase purity assay described here.
